Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
nimotuzumab + toripalimab + cisplatin + albumin paclitaxel + capecitabine
- Development stage
- Unknown
- Lead developer
- Sun Yat-sen University
- Modality
- Nanoparticles → Drug Delivery Systems, Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intravenous, Oral
01
Overview
This multi-drug chemo-immunotherapy regimen is being investigated by Sun Yat-sen University for the treatment of high-risk locally advanced nasopharyngeal carcinoma (LANPC). The regimen combines two targeted biologics—nimotuzumab (an EGFR inhibitor) and toripalimab (a PD-1 checkpoint inhibitor)—with a triplet chemotherapy backbone consisting of cisplatin, albumin-bound paclitaxel (nab-paclitaxel), and capecitabine (the TPC regimen). This intensive induction therapy aims to improve outcomes in patients with high-risk disease before they undergo radical radiotherapy. The combination leverages synergistic effects between immune checkpoint blockade, targeted growth factor inhibition, and cytotoxic chemotherapy to maximize tumor reduction and enhance anti-tumor immunity.
- Other names
- TPC plus nimotuzumab and toripalimabTPC-Nimotuzumab-ToripalimabTriprolizumab
02
Targets
PDCD1 (Programmed cell death protein 1 receptor)TS (Thymidylate synthase)DNATUBB (Tubulin (alpha and beta subunits))EGFR T790M (Epidermal growth factor receptor T790M mutant)
Beyond the preview
Go deeper on nimotuzumab + toripalimab + cisplatin + albumin paclitaxel + capecitabine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on nimotuzumab + toripalimab + cisplatin + albumin paclitaxel + capecitabine.